Abstract The purpose of the present study was to determine if the lacrimal gland contains 5-bromo-2′-deoxyuridine (BrdU)-label retaining cells and if they are involved in tissue repair. Animals were pulsed daily with BrdU injections for 7 consecutive days. After a chase period of 2, 4, or 12 weeks, the animals were sacrificed and the lacrimal glands were removed and processed for BrdU immunostaining. In another series of experiments, the lacrimal glands of 12-week chased animals were either left untreated or were injected with interleukin 1 (IL-1) to induce injury. Two and half days post-injection, the lacrimal glands were removed and processed for BrdU immunostaining. After 2 and 4 weeks of chase period, a substantial number of lacrimal gland cells were BrdU 
Introduction
The tear film helps protect and nourish the epithelial cells in the ocular surface (Tiffany 2008) . It consists of three interacting layers: an outer lipid layer secreted by the meibomian glands, a middle aqueous layer secreted by the main lacrimal gland and an inner mucous layer secreted by the corneal and conjunctival epithelial cells (Bron et al. 2004; Gipson and Argueso 2003; Hodges and Dartt 2003; Tiffany 2008) . The lacrimal gland is a tubuloacinar tissue responsible for secretion of the proteins, electrolytes and water, which make up the middle aqueous layer of the tear film (Dartt 2009; Hodges and Dartt 2003) . The lacrimal gland is composed primarily of acinar epithelial cells (>80%) but also includes ductal epithelial cells, myoepithelial cells and plasma cells (Dartt 2009; Hodges and Dartt 2003) .
Dry eye syndrome is the result of the production of tears in inadequate quantity or of inadequate quality (Pflugfelder 2004; Stern et al. 1998; Zoukhri 2006) . A major subtype of dry eye syndrome is the aqueous deficient type of dry eye also called keratoconjunctivitis sicca (Schaumberg et al. 2003 (Schaumberg et al. , 2009 . Chronic inflammation of the lacrimal gland can lead to insufficient tear production (Pflugfelder 2004; Stern et al. 1998; Zoukhri 2006) . Lacrimal gland inflam-mation is characterized by the presence of focal lymphocytic infiltrates, increased production of proinflammatory cytokines and destruction of the tear-producing parenchymal cells (Pflugfelder 2004; Stern et al. 1998; Zoukhri 2006) . Dry eye syndrome due to lacrimal gland disease is often encountered in autoimmune diseases (such as Sjög-ren's syndrome, sarcoidosis and rheumatoid arthritis), following organ transplantation (graft-versus-host disease) or viral infections (hepatitis, HIV) (Calissendorff et al. 1989; De Vita et al. 2002; DeCarlo et al. 1995; Drosos et al. 1989; Ogawa and Kuwana 2003; Pflugfelder 2004; Stern et al. 1998; Zoukhri 2006) .
Stem cells have been reported in various adult tissues including the salivary glands, the pancreas, the liver, the intestines and the mammary glands (Alison et al. 1997; Bjerknes and Cheng 2002; Hisatomi et al. 2004; Okumura et al. 2003; Zhang et al. 2005) . In the salivary glands and the pancreas, stem/progenitor cells have been identified as being active participants in tissue repair after experimentally induced injury (Hisatomi et al. 2004; Kishi et al. 2006; Okumura et al. 2003; Zhang et al. 2005) . Furthermore, adult stem/progenitor cells have been demonstrated to have the capacity to differentiate into both acinar and ductal cells (Hisatomi et al. 2004; Kishi et al. 2006; Okumura et al. 2003; Zhang et al. 2005) . In various tissues, stem cells have been shown to be label-retaining, slow-cycling cells. These include the pancreas, the kidney, the salivary glands, the lung, the eye, the heart and mammary glands (Duvillie et al. 2003; Gomperts and Strieter 2007; Kimoto et al. 2008; Maeshima et al. 2003; Meinhardt et al. 2011; Smith 2005; Wei et al. 1995) . Stem cells are thought to both divide at a slower rate compared to transit cells and to divide asymmetrically (Kume 2005; Poulsom et al. 2002) . The most common method for identifying slow-cycling cells consists in using the 5-bromo-2′-deoxyuridine (BrdU) pulse-chase technique (Cotsarelis et al. 1989 (Cotsarelis et al. , 1990 . BrdU is a thymidine analog that incorporates into the DNA of dividing cells (during the S phase of the cell cycle), rendering them detectable by immunohistochemical means. Because subsequent cell divisions in the absence of label (chase period) dilute the incorporated BrdU, only cells with the lowest replication profile are detected (Cotsarelis et al. 1989 (Cotsarelis et al. , 1990 Potten et al. 1978) .
It was recently reported that mesenchymal stem cells contribute to lacrimal gland repair following experimentally induced injury Zoukhri et al. 2008) . It was shown that, during the repair phase, the number of stem/progenitor cells, as identified by the expression of the stem cell marker nestin, was increased Zoukhri et al. 2008) . In the present study, we aimed to determine the presence of BrdU-label retaining cells in the lacrimal gland. Animals were pulsed with BrdU for a period of 7 days and then chased for 2, 4 or 12 weeks, to identify the population of slow-cycling label-retaining cells. Additionally, we investigated the involvement of BrdU-label retaining cells in lacrimal gland repair following experimentally induced injury. Our results show that the lacrimal gland contains BrdUlabel retaining cells that are mobilized during tissue repair to generate acinar, ductal and myoepithelial cells.
Materials and methods
5-Bromo-2′-deoxyuridine (BrdU) solution was obtained from Invitrogen (Carlsbad, CA, USA). All other chemicals, unless otherwise specified, were obtained from Fisher Scientific or Sigma (St. Louis, MO, USA). Table 1 lists the primary antibodies used in these studies. Alexa Fluor 488 and Alexa Fluor 594 conjugated secondary antibodies (1:100; Invitrogen); and FITC conjugated secondary antibodies (1:100; Jackson ImmunoResearch, Westgrove, PA, USA) were used for detection.
In vivo BrdU labeling and lacrimal gland injury
Female BALB/c mice (8-10 weeks old) were purchased from Taconic (Germantown, NY, USA). Animals were maintained in constant temperature rooms with fixed light/ dark intervals of 12 h length and were fed ad libitum. All experiments were in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Tufts Medical Center Animal Care and Use Committee.
BrdU (50 mg/kg body weight) was injected intraperitoneally into mice daily for 7 consecutive days. The mice were sacrificed after a 2-, 4-, or 12-week chase period, the exorbital lacrimal glands removed and processed for BrdU immunostaining. The pulse and chase time periods were chosen based on reports in the literature (Alison et al. 1997; Bjerknes and Cheng 2002; Chan and Gargett 2006; Hisatomi et al. 2004; Okumura et al. 2003; Zhang et al. 2005) . To investigate the role of BrdU-label retaining cells in tissue repair, animals from the 12-week chase group were anesthetized and the exorbital lacrimal glands were injected, in a total volume of 2 μl, with recombinant human IL-1α (1 μg, a generous gift from the BRB Preclinical Repository of the National Cancer Institute), as previously described (Zoukhri et al. 2007 (Zoukhri et al. , 2008 . Animals (from the 12-week chase group) whose lacrimal glands were left untreated were used as controls. Two and half days later (at the peak of tissue repair; (Zoukhri et al. 2007 (Zoukhri et al. , 2008 , the lacrimal glands were removed and processed for histopathology (to determine tissue repair) or for BrdU immunostaining.
Histopathology and immunostaining
Lacrimal glands were fixed overnight at 4°C in 4% formaldehyde made in phosphate buffered saline (PBS, containing in mM: 145 NaCl, 7.3 Na 2 HPO 4 and 2.7 NaH 2 PO 4 at pH 7.2). Paraffin sections of the lacrimal gland (6 μm) were deparaffinized and rehydrated using graded alcohols. For histopathology experiments, paraffin sections of the lacrimal gland were processed for hematoxylin and eosin staining. For immunostaining experiments, the slides were first subjected to microwave pretreatment (20 min) with an antigen retrieval solution (citrate buffer, pH 6.0). After 3 washes in PBS, slides for single BrdU labeling were treated with proteinase K for 10 min while slides for double-labeling experiments were treated with proteinase K for 2 min. After 3 washes with PBS, nonspecific binding sites were blocked and tissue was permeabilized for 1 h using 0.1% Triton-X and 10% normal donkey serum diluted in PBS. The slides were then incubated overnight at 4°C with the indicated primary antibody diluted in PBS with 0.1% normal donkey serum. After 3 washes in PBS, slides were incubated for 60 min at room temperature with the appropriate secondary antibody diluted 1:100 in 0.1% normal donkey serum. After 3 washes in PBS, coverslips were mounted with a Vectashield mounting medium containing 4',6-diamidino-2-phenylindole (DAPI to stain cell nuclei; Vector Laboratories, Burlingame, CA, USA). Sections were viewed using a Nikon UFXII microscope equipped for epiillumination. Omission of the primary antibody or incubation with irrelevant immunoglobulins was performed for negative control experiments.
Cell counting
Counting of BrdU-labeled cells was conducted in a blinded manner. Multiple slides, with 4-5 sections prepared from lacrimal glands removed 2, 4, or 12 weeks post-BrdU pulse, were stained for BrdU immunoreactivity. All slides were processed on the same day in order to control for staining variability. Similarly, sections from control and IL-1 injected glands were processed on the same day. From each slide, one section was chosen at random and the number of BrdUlabeled nuclei in the entire section counted. DAPI-stained nuclei of the entire section were then digitally captured using a Spot digital camera (Diagnostic Instruments, Sterling Heights, MI, USA) and the surface area determined using the camera's software, as shown in Fig. 1c . True positive staining was distinguished from nonspecific staining by switching between FITC (BrdU stain, green) and DAPI counterstaining (nuclei, blue) in order to ensure colocalization of both stains (Fig. 1a, b Where appropriate, data are expressed as means ± SEM. The data were statistically analyzed using one-way analysis of variance (ANOVA) followed by post-hoc t test. Values of p<0.05 were considered to be significant.
Results

Identification of BrdU-label retaining cells in the lacrimal gland
In previous studies, it was suggested that the murine lacrimal gland contains stem/progenitor cells that are mobilized during tissue repair ). These cells were identified in injured lacrimal glands by immunostaining for markers known to be expressed in stem/progenitor cells such as nestin, Sca-1 and ABCG2 (Zoukhri et al. 2008) . However, cells bearing these markers were almost undetectable in noninjured lacrimal glands and hence the presence of resident stem/progenitor cells in this tissue is still unclear (Zoukhri et al. 2008) . Therefore, we used the BrdU-labeling technique in order to identify slow-cycling label-retaining cells, a unique property of stem/progenitor cells. Animals were pulsed for 1 week with daily injections of BrdU and after a 2-, 4-, or 12-week chasing period, the lacrimal glands were removed and the number of BrdU + cells quantified. The pulse and chase time periods were chosen based on reports in the literature (Alison et al. 1997; Bjerknes and Cheng 2002; Chan and Gargett 2006; Hisatomi et al. 2004; Okumura et al. 2003; Zhang et al. 2005) .
The photomicrographs depicted in Fig. 2a-d show that following the 2-and 4-week chase periods, multiple BrdU + cells could be observed in any given lacrimal gland lobule. Fig. 2a-g show that the number of BrdU + cells was high after 2 weeks of chase, decreased slightly by the 4th week (Fig. 2g) . At 12 weeks, the average number of BrdU + cells/mm 2 declined by 97% to 0.38±0.06 (Fig. 2g) . Data analysis using one-way ANOVA showed a statistically significant difference between the 3 groups (p= 0.0012). The post-hoc t test found a statistically significant difference between the 2-and 12-week values and between the 4-and 12-week values (p<0.0001; Fig. 2g) .
These results further confirm that stem/progenitor cells are present in the murine lacrimal gland. They also show that the 12-week chase period is optimal for dilution of the BrdU stain and detection of slow-cycling cells in the lacrimal gland.
Involvement of BrdU-label retaining cells in lacrimal gland repair
In another series of experiments, we aimed to determine if the BrdU-label retaining cells were involved in lacrimal gland repair following experimentally induced injury. We previously established that a single injection of IL-1 into the lacrimal gland results in a severe inflammatory response accompanied by massive cell loss followed by mobilization of stem/progenitor cells that initiate tissue repair Zoukhri et al. 2008) . Lacrimal gland regeneration in female BALB/c is achieved in 6-7 days post IL-1 injection with the peak of tissue repair (i.e., mobilization of stem/ progenitor cells, deposition of extracellular matrix material and induction of cell proliferation) occurring between 2 and 3 days post injury Zoukhri et al. 2008 ). Thus, we used this experimental paradigm to determine if label retaining cells were mobilized (i.e., the number of BrdU + cells would increase) 2.5 days following injection of IL-1. We used 7-day BrdU pulsed 12-week chased animals whose lacrimal glands were either left untreated or received a single injection of IL-1. The lacrimal glands were removed 2.5 days later and processed for histopathology and immunostaining. As shown in Fig. 3a-d (and in accordance with the data shown in Fig. 2 ), in control lacrimal glands very few cells were BrdU positive (Fig. 3a-d ) in contrast to glands prepared from IL-1-treated glands where the BrdU label was abundant (Fig. 3e-h ). When the number of BrdU positive cells was quantified, control glands had 0.41±0.09 BrdU + cells/mm 2 (Fig. 3i) . In injured lacrimal glands, there was a significant 7.12-fold increase in the number of BrdU labeled cells (2.91±0.62 BrdU + cells/ mm 2 ; Fig. 3i ). These results suggest that injury stimulates BrdU-label retaining cells to proliferate. To test this hypothesis, we double-labeled lacrimal gland sections for BrdU and the proliferation marker, Ki67. We previously showed increased Ki67 staining during repair of the Lacrimal glands from BrdU pulsed/chased animals were fixed and stained for BrdU immunoreactivity and nuclei were counterstained with DAPI, as described in "Materials and methods". True positive BrdU staining was defined when BrdU immunoreactivity (a, green) colocalized with DAPI (b, blue) staining. Scale bar 100 μm. The total area of the gland, visualized with DAPI (c), was determined using the SPOT camera software and then data were expressed as number of BrdU + cells /mm lacrimal gland (Zoukhri et al. 2007 ). As shown in Fig. 4 , cells staining positive for both BrdU and Ki67 could be seen, suggesting that BrdU-positive cells are indeed capable of proliferating. Fig. 2 Identification of BrdU-label retaining cells in the murine lacrimal gland. Lacrimal glands were removed from 7-day BrdU pulsed animals after a chase period of 2, 4, or 12 weeks and processed for BrdU staining, as described in "Materials and methods". Cell nuclei were counterstained with DAPI. a-f Representative photomicrographs of BrdU staining in glands removed from 2, 4, or 12 weeks post the 7-day BrdU pulse. Arrows point to examples of BrdU stained nuclei. Scale bar 100 μm. g The number of BrdU + cells was quantified as described in "Materials and methods". Data are means ± SEM (n=3) and were statistically analyzed using one-way analysis of variance (ANOVA) followed by post-hoc t test
We next aimed to determine the cell type that bears the BrdU staining during tissue repair. The lacrimal gland is composed of acinar, ductal and myoepithelial cells (Hodges and Dartt 2003) . The acinar and ductal cells can be easily distinguished from each other based on their morphology but to unambiguously identify the myoepithelial cells one has to stain for α-smooth muscle actin (α-SMA) (Lemullois et al. 1996) . Lacrimal glands removed from BrdU pulsed, 12-week chased and IL-1 injected animals were processed for double immunostaining for BrdU and β-actin (acini and ducts) or BrdU and α-SMA (myoepithelial cells). Figure 5 shows that BrdU immunoreactivity can be seen associated with all three types of lacrimal gland cells: acinar (Fig. 5a-d) , ductal ( Fig. 5e-h ) and myoepithelial cells (Fig. 5i-l) . In addition, BrdU immunoreactivity was also associated with stromal cells scattered in the surrounding connective tissue (Fig. 5m-p) . It should be noted that only a very few ducts had BrdU + cells within them. Indeed, when the amount of BrdU staining was quantified per cell type (acinar, myoepithelial, ductal and stromal) only 0.4% of the BrdU stain was found to be associated with ducts (Fig. 5q) . In contrast, the acinar cells accounted for most of the staining (58.2±3.6%) followed by the myoepithelial cells (26.4±4.1%) and then the stromal cells (15.0±3.0%). These findings are not surprising since acini account for >80% of the lacrimal gland parenchyma and each acinus is surrounded by at least one myoepithelial cell (Dartt 2009; Hodges and Dartt 2003) . Moreover, in our model of tissue injury, the ductal cells are not lost (in contrast to the acinar and myoepithelial cells) following IL-1 injection and this could account for the low occurrence of BrdU staining in ductal cells observed during repair (Zoukhri et al. 2008 , Zoukhri et al. 2007 .
In summary, these results suggest that in the murine lacrimal gland, the BrdU-label retaining, slow-cycling cells can differentiate, following tissue insult, into the three major cell types: acinar, myoepithelial and ductal cells. Fig. 3 Tissue injury increases the number of BrdU + cells. Lacrimal glands of 7-day pulsed/12-week chased animals were either left untreated (control) or were injected with IL-1 to induce tissue injury. The lacrimal glands were removed 2.5 days after injury and processed for BrdU staining, as described in "Materials and methods". a-d Representative photomicrographs of BrdU staining in glands removed from control animals. e-h Representative photomicrographs of BrdU staining in glands removed from IL-1 injected animals. Arrows point to examples of BrdU stained nuclei. Scale bar 100 μm. i The number of BrdU + cells was quantified as described in "Materials and methods". Data are means ± SEM (n=3) and were statistically analyzed using unpaired Student's t test
Discussion
The BrdU pulse/chase technique has been reliably used to detect label-retaining slow-cycling cells in several adult tissues such as the pancreas, the kidney, the salivary glands, the lung, the eye, the heart and mammary glands (Duvillie et al. 2003; Gomperts and Strieter 2007; Kimoto et al. 2008; Maeshima et al. 2003; Meinhardt et al. 2011; Smith 2005; Wei et al. 1995) . Some of these cells display pluripotency or a certain degree of plasticity. Indeed, several studies have reported the involvement of labelretaining cells in tissue repair (Blanpain et al. 2007; Duvillie et al. 2003; Forbes et al. 2002; Gomperts and Strieter 2007; Kimoto et al. 2008; Poulsom et al. 2002) . In the present study, we aimed to identify BrdU-label retaining cells in the murine lacrimal gland and to investigate their role in tissue repair.
Ongoing studies in our laboratory document that the murine lacrimal gland is capable of repair following experimentally induced injury Zoukhri 2010; Zoukhri et al. 2007 Zoukhri et al. , 2008 . It was reported that repair of the lacrimal gland involved the mobilization of mesenchymal stem cells (MSCs). These cells expressed the type VI intermediate filament protein nestin, which is also a marker of stem cells, whose expression was up-regulated during the peak of the repair phase (2-3 days following injury) (Zoukhri et al. 2008 ). More recently, it was shown that, during tissue repair, lacrimal gland cells undergo epithelial-mesenchymal transition (EMT) to generate MSCs that expressed the type III intermediate filament protein vimentin along with nestin and α-SMA . The results from the current studies confirm and extend those findings by showing the presence and participation of BrdU-label retaining cells in lacrimal gland repair following experimentally induced injury.
Since BrdU only labels cells that are dividing, the substantial BrdU staining after the 2-and 4-week chase periods suggests that there is significant cell turnover in the murine lacrimal gland, consistent with findings in the murine submandibular gland (Kim et al. 2008) . Because subsequent cell divisions in the absence of label (chase period) dilute the incorporated BrdU, only cells with the lowest replication profile or those dividing asymmetrically are detected after a prolonged (12-week) chase period (Cotsarelis et al. 1989 (Cotsarelis et al. , 1990 Potten et al. 1978) . In other words, our data suggest the existence in the murine lacrimal gland of a population of fast-cycling transit cells that did not retain the label long term and a rare population of slowcycling label-retaining cells that may represent adult lacrimal gland stem/progenitor cells. These results are in accordance with those reported in the murine submandibular gland where the number of BrdU + cells after a 2-week chase amounted to 9.88±2.18% and then decreased to 1.23± 0.09% after a 7-week chase (Kim et al. 2008) .
To investigate whether the label-retaining cells had a role in tissue repair, the lacrimal glands of animals pulsed with BrdU and chased for 12 weeks were injected with IL-1 to induce injury. In mice, IL-1 injection induces a severe inflammatory response leading to destruction of acinar and myoepithelial cells followed by a repair phase that peaks Fig. 4 Proliferation of BrdU-label retaining cells. Lacrimal glands removed from 7-day pulsed/12-week chased animals and injected with IL-1 were processed for BrdU (a, green) and Ki67 (b, red) double-staining, as described in "Materials and methods". Nuclei were counterstained with DAPI (c, blue). Arrows indicate two BrdU and Ki67 double-labeled cells. Insets show higher magnification of the doubly-labeled cells. Scale bar 50 μm Fig. 5 Distribution of the BrdU label during tissue repair. Injured lacrimal glands of 7-day pulsed/12-week chased animals were removed 2.5 days after injury and processed for either BrdU/β-actin (to identify acini and ducts) or BrdU/α-SMA (to identify myoepithelial cells) double staining, as described in "Materials and methods". ap Representative photomicrographs of BrdU staining associated with acinar (a-d), ductal (e-h), myoepithelial (i-l) and stromal (m-p) cells. Inset in (l) depicts a higher magnification of the area marked by an asterisk (*) highlighting co-localization of the BrdU stain with that for α-SMA. Scale bar 50 μm. q The number of BrdU + cells associated with acinar, myoepithelial, ductal and stromal cells was quantified, as described in "Materials and methods". Data are means ± SEM (n=3) between 2 and 3 days after injection (Zoukhri et al. 2007 (Zoukhri et al. , 2008 . Our data show that, following injection of IL-1, the number of BrdU-label retaining cells increased significantly compared to non-injured glands. This suggests that injury stimulates BrdU-label retaining cells to proliferate. Using antibodies against Ki67, a marker of proliferation, we were able to show that some of the BrdU-positive cells were also positive for Ki67.
It was reported that, in the submandibular gland, labelretaining cells could be observed in multiple structures including acini, ducts and myoepithelial cells (Kim et al. 2008; Kimoto et al. 2008) . Double staining experiments for β-actin/BrdU and α-SMA/BrdU showed that labelretaining cells could be mobilized following lacrimal gland injury to differentiate into acinar, ductal and myoepithelial cells. In addition, a substantial amount of BrdU label was also seen associated with stromal cells. One limitation of the present study is that we could not determine what compartment the BrdU label was associated with since, in uninjured tissue, the number of BrdU + cells was very low. Another limitation inherent to the BrdU pulse/technique is that one cannot rule out the contribution of circulating (i.e., non-resident lacrimal gland) BrdU + cells in tissue repair. In summary, our results show that the murine lacrimal gland contains BrdU-label retaining cells that are mobilized following injury to generate acinar, ductal and myoepithelial cells. Further studies are needed to determine the fate of the BrdU-label retaining cells, i.e., are these cells the same as the one identified by nestin staining and/or do they undergo EMT to generate mesenchymal stem cells during lacrimal gland repair.
